Coherus BioSciences Inc (CHRS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $81.21M
Last updated: Nov 17, 2026 at 11:04 AM ET
Coherus BioSciences Inc (CHRS) Stock Forecast
Analysts expect Coherus BioSciences (CHRS) to earn -$0.86 per share in the fiscal year ending Dec 31, 2026, on revenue of $56.74M. Of 6 analysts, 5 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 83% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 16.7% |
| Buy | 4 | 66.7% |
| Hold | 1 | 16.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 63.7%.
- Fiscal year ending Dec 31, 2026
- -$0.86
- EPS consensus, revenue $56.74M
- Fiscal year ending Dec 31, 2027
- -$0.63
- EPS consensus, revenue $92.89M
- Next report
- Mar 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.86 | -$0.87 to -$0.84 | 2 | $56.74M | $56.39M to $57.04M | 3 |
| Dec 31, 2027 | -$0.63 | -$0.65 to -$0.61 | 2 | $92.89M | $78.02M to $117.00M | 6 |
Quarterly Estimates
The EPS consensus rises from -$0.22 for the quarter ending Dec 31, 2026 to -$0.20 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.22 | -$0.28 to -$0.19 | 9 | $17.43M | $15.58M to $19.84M | 8 |
| Mar 31, 2027 | -$0.20 | -$0.20 to -$0.20 | 1 | $18.49M | $16.40M to $20.50M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.79.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.86 | -$0.75 | -$0.75 | -$0.75 | -$0.79 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.63 | -$1.02 | -$1.02 | -$1.02 | -$0.81 | N/A |
| Quarter ending Mar 31, 2027 | -$0.20 | -$0.26 | -$0.26 | -$0.26 | -$0.21 | N/A |
Frequently Asked Questions About CHRS
What is the CHRS stock forecast?
Consensus analyst estimates put Coherus BioSciences's EPS at -$0.86 for the fiscal year ending Dec 31, 2026, on revenue of $56.74M. The consensus rating from 6 analysts is Buy.
How do analysts rate CHRS stock?
Of 6 analysts covering Coherus BioSciences, 1 rates it Strong Buy, 4 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CHRS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.86, with estimates from -$0.87 to -$0.84 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.63, with estimates from -$0.65 to -$0.61 from 2 analysts.
What revenue do analysts expect from Coherus BioSciences next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $56.74M, with estimates from $56.39M to $57.04M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $92.89M, with estimates from $78.02M to $117.00M.
How many analysts cover CHRS?
6 analysts rate Coherus BioSciences stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CHRS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors